ABEONA THERAPEUTICS INC. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
ABEONA THERAPEUTICS INC. (ABEO) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $3.67 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2022-03-31
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2021-12-31 was $548.00K, a 63.99% decline year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2021-09-30 was $1.15M, a 614.29% increase year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2021-06-30 was $1.10M, a 488.77% increase year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2021-03-31 was $867.00K, a 86.85% increase year-over-year.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2021 was $3.67M, a 57.07% increase from fiscal 2020.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2020 was $2.33M, a 159.62% increase from fiscal 2019.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2019 was $899.00K, a 30.67% increase from fiscal 2018.
- ABEONA THERAPEUTICS INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2018 was $688.00K, a 45.91% decline from fiscal 2017.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2021-12-31 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.70M derived: sum of 2 quarters · filed 2022-03-31 | $2.80M derived: sum of 3 quarters · filed 2022-03-31 | $3.67M 10-K · filed 2022-03-31 |
| 2021-09-30 | $1.15M 10-Q · filed 2021-11-15 | $2.25M derived: sum of 2 quarters · filed 2021-11-15 | $3.12M 10-Q · filed 2021-11-15 | $4.64M derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-06-30 | $1.10M 10-Q · filed 2021-07-28 | $1.97M 10-Q · filed 2021-07-28 | $3.49M derived: sum of 3 quarters · filed 2022-03-31 | $3.65M derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | $867.00K 10-Q · filed 2021-05-17 | $2.39M derived: sum of 2 quarters · filed 2022-03-31 | $2.55M derived: sum of 3 quarters · filed 2022-03-31 | $2.74M derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.68M derived: sum of 2 quarters · filed 2022-03-31 | $1.87M derived: sum of 3 quarters · filed 2022-03-31 | $2.33M 10-K · filed 2022-03-31 |
| 2020-09-30 | $161.00K 10-Q · filed 2021-11-15 | $348.00K derived: sum of 2 quarters · filed 2021-11-15 | $812.00K 10-Q · filed 2021-11-15 | $1.36M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $187.00K 10-Q · filed 2021-07-28 | $651.00K 10-Q · filed 2021-07-28 | $1.20M derived: sum of 3 quarters · filed 2021-07-28 | $1.30M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $464.00K 10-Q · filed 2021-05-17 | $1.01M derived: sum of 2 quarters · filed 2021-05-17 | $1.11M derived: sum of 3 quarters · filed 2021-05-17 | $1.19M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $649.00K derived: sum of 2 quarters · filed 2021-03-24 | $727.00K derived: sum of 3 quarters · filed 2021-03-24 | $899.00K 10-K · filed 2021-03-24 |
| 2019-09-30 | $98.00K 10-Q · filed 2020-11-09 | $176.00K derived: sum of 2 quarters · filed 2020-11-09 | $348.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $78.00K 10-Q · filed 2020-08-10 | $250.00K derived: sum of 2 quarters · filed 2020-08-10 | ||
| 2019-03-31 | $172.00K 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $688.00K 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $172.00K 10-Q · filed 2019-11-12 | $344.00K derived: sum of 2 quarters · filed 2019-11-12 | $516.00K derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $172.00K 10-Q · filed 2019-11-12 | $344.00K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $172.00K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $1.27M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |